Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

OBJECTIVE: We investigated lenvatinib plus programmed cell death-1 (PD-1) inhibitors as a first-line treatment for initially unresectable biliary tract cancer (BTC). METHODS: In this Phase II study, adults with initially unresectable BTC received lenvatinib (body weight ≥60 kg, 12 mg; <60 kg, 8 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qiyi, Liu, Xingyu, Wei, Shumei, Zhang, Lufei, Tian, Yang, Gao, Zhenzhen, Jin, Ming, Yan, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651538/
https://www.ncbi.nlm.nih.gov/pubmed/34900698
http://dx.doi.org/10.3389/fonc.2021.751391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651538/
https://www.ncbi.nlm.nih.gov/pubmed/34900698
http://dx.doi.org/10.3389/fonc.2021.751391

Ejemplares similares